Repositorio Institucional Fleni
Not a member yet
602 research outputs found
Sort by
Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile
No full textBackground: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile
has not been reported. Objective: To evaluate the effectiveness of natalizumab treatment in PwRMS in Argentina and Chile, in clinical
practice. Methods: We conducted a multicenter retrospective and observational study. We reviewed the medical records of PwRMS who
had been treated with natalizumab for at least one year, without any interruption in MS treatment that lasted more than 12 weeks. We
analyzed changes in annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score and magnetic resonance imaging (MRI).
Results: We enrolled 117 PwRMS treated with natalizumab. Natalizumab treatment was associated with a significant reduction in ARR
from baseline after one year and two years of treatment (from 1.97 to 0.06 and 0.09 respectively; p<0.01 at each time point). From baseline,
EDSS scores were reduced by 0.71 and 0.73 points at one and two years, respectively (p<0.01). No worsening of disability was observed
in 82.9 and 67.5% of PwRMS at one and two years, respectively. The improvement in disability was 44.4% at one year and 39.3% at two
years. During natalizumab treatment, the number of relapse-related hospitalizations was significantly reduced (p<0.01). MRI lesions (new/
enlarging T2 or gadolinium-enhancing) were significantly reduced, compared with baseline. No evidence of disease activity was observed
in 65% at two years of natalizumab treatment. Conclusions: Natalizumab significantly reduced disease activity in PwRMS in Argentina and
Chile, in clinical practice. Natalizumab also decreased the number of hospitalizations compared with pre-natalizumab treatment.Fil: Ysrraelit, Maria Célica. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Caride, Alejandro. Hospital Aleman; Argentina.Fil: Sinay, Vladimiro. Fundación Favaloro; Argentina.Fil: Rivera Kindel, Mario. Clínica Dávila; Chile.Fil: Halfon, Mario Javier. British Hospital of Buenos Aires; Argentina.Fil: Patrucco, Liliana. Hospital Italiano de Buenos Aires; Argentina
Pseudoaneurysm following Surgical Resection of Craniopharyngioma. What Is the Best Management?
No full textCraniopharyngiomas are benign tumors of the sellar and parasellar region for which surgical resection remains the treatment of choice. There are many publications on the most frequent postoperative complications, but few reports on subclinical lesions affecting the arteries of the circle of Willis, despite their high morbidity and mortality rate. Trauma-induced aneurysms are infrequent, representing less than 1% of intracranial aneurysms. Iatrogenic intracranial pseudoaneurysms are a subtype of surgically induced aneurysms developed as a result of direct injury to the arterial wall or after dissection of tumors adherent to the vessel adventitia. The natural history of these lesions is not well known because their incidence is extremely low. We report two cases of postoperative aneurysms of the internal carotid artery after craniopharyngioma resection and a brief review on the management of such lesions.Fil: Marcó del Pont, Francisco. Fleni. Departamento de Neurocirugía; Argentina.Fil: Villalonga, Juan Francisco. Fleni. Departamento de Neurocirugía; Argentina.Fil: Sáenz, Amparo. Fleni. Departamento de Neurocirugía; Argentina. Hospital de Pediatría Juan P. Garrahan. Departamento de Neurocirugía; Argentina.Fil: Caffaratti, Guido. Fleni. Departamento de Neurocirugía; Argentina.Fil: Condomí Alcorta, Santiago G. Fleni. Departamento de Neurocirugía; Argentina.Fil: Cervio, Andrés Eduardo. Fleni. Departamento de Neurocirugía; Argentina
Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina
No full textAbstract
We aimed to examine treatment interventions implemented in patients experiencing neuromyelitis optica spectrum disorders (NMOSD) attacks (frequency, types, and response).
Methods
Retrospective study. Data on patient demographic, clinical and radiological findings, and administered treatments were collected. Remission status (complete [CR], partial [PR], no remission [NR]), based on changes in the EDSS score was evaluated before treatment, during attack, and at 6 months. CR was analyzed with a generalized estimating equations (GEEs) model.
Results
A total of 131 patients (120 NMOSD and 11 myelin oligodendrocyte glycoprotein-antibody-associated diseases [MOGAD]), experiencing 262 NMOSD-related attacks and receiving 270 treatments were included. High-dose steroids (81.4%) was the most frequent treatment followed by plasmapheresis (15.5%). CR from attacks was observed in 47% (105/223) of all treated patients. During the first attack, we observed CR:71.2%, PR:16.3% and NR:12.5% after the first course of treatment. For second, third, fourth, and fifth attacks, CR was observed in 31.1%, 10.7%, 27.3%, and 33.3%, respectively. Remission rates were higher for optic neuritis vs. myelitis (p < 0.001). Predictor of CR in multivariate GEE analysis was age in both NMOSD (OR = 2.27, p = 0.002) and MOGAD (OR = 1.53, p = 0.03).
Conclusions
This study suggests individualization of treatment according to age and attack manifestation. The outcome of attacks was generally poor.Fil: Carnero Contentti, Edgar. Hospital Alemán. Departamento de Neurociencias. Unidad de Neuroinmunología; Argentina.Fil: López, Pablo Adrián. Hospital Alemán. Departamento de Neurociencias. Unidad de Neuroinmunología; Argentina.Fil: Pettinicchi, Juan Pablo. Hospital Alemán. Departamento de Neurociencias. Unidad de Neuroinmunología; Argentina.Fil: Criniti, Juan. Hospital Alemán. Departamento de Neurociencias. Unidad de Neuroinmunología; Argentina.Fil: Pappolla, Agustín. Hospital Italiano de Buenos Aires. Servicio de Neurología; Argentina.Fil: Miguez, Jimena. Hospital Italiano de Buenos Aires. Servicio de Neurología; Argentina.Fil: Patrucco, Liliana. Hospital Italiano de Buenos Aires. Servicio de Neurología; Argentina.Fil: Cristiano, Edgardo. Centro de esclerosis múltiple de Buenos Aires; Argentina.Fil: Liwacki, Susana. Clínica Universitaria Reina Fabiola. Servicio de Neurología; Argentina.Fil: Tkachuk, Verónica A. Hospital de Clínicas José de San Martín. Servicio de Neurología. Sección de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Balbuena Aguirre, María Eugenia. Hospital de Clínicas José de San Martín; Argentina.Fil: Vrech, Carlos. Sanatorio Allende. Departamento de Enfermedades Desmielinizantes; Argentina.Fil: Deri, Norma. Centro de Investigaciones Diabaid; Argentina.Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Marrodán, Mariano. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Ysrraelit, María Célica. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Leguizamon, Felisa. Hospital de Agudos Dr. Teodoro Álvarez; Argentina.Fil: Luetic, Geraldine. Hospital de Agudos Dr. Teodoro Álvarez; Argentina.Fil: Menichini, María L. Sanatorio Británico; Argentina.Fil: Tavolini, Darío. INECO; Argentina
Abstract P385: Stroke-Related Hospital Admissions During Covid-19 Pandemic in the Latin American Stroke Registry (LASE)
No full textBackground: COVID-19 pandemic has forced important changes in health care worldwide. Stroke care networks have been affected, especially acute admissions and ancillary tests availability. We assessed the impact of the pandemic and the lockdowns imposed in stroke admissions in Latin America.
Methods: A multinational study (7 countries, 18 centers) of patients admitted since the pandemic outbreak (January - June 2020). These cases were compared with the same period in 2019. We also assessed patterns during the strictest lockdown period (March-June 2020). Number of cases, stroke etiology and severity, acute care and functional outcomes were compared per periods, months, centers and countries.
Results: There were 1863 stroke cases in 2019 and 1781 cases in 2020 (p=0.02). We found a significant increase in strokes of undetermined etiology due to incomplete studies in 2020 [16.8% vs 27.6%, p<0.001]). Most countries reported decreases in all-type stroke admissions, except México and Brasil (16% and 36% increases in admissions, respectively). There were no significant differences among months. All-type mortality increased (6.2% vs. 12.6%, p<0.001), and poor functional outcome (mRs 3-6) increased from 32.2% to 38.8% (p=0.007) in 2020. During the period of strict lockdown (March-June 2020), ischemic stroke admissions during the first 24 hours of onset (68.3% vs. 64.4%, p=0.1) and in-hospital stroke code activation (35.1% vs. 27.6%, p=0.005) diminished compared to 2019 period. No differences in total reperfusion treatment rates were observed, with similar door-to-needle and door-to-groin times in both periods.
Conclusions: All-type stroke admissions diminished only slightly during the first months of the COVID-19 pandemic. However, in this region, we found substantial deficiencies in stroke work-up, poor short-term outcome and increased mortality.Fil: Pujol Lereis, Virginia Andrea. Fleni. Centro Integral de Neurología Vascular; Argentina.Fil: Flores, Alan. Hospital Joan XXIII; España.Fil: AArauz-Gongora, Antonio. Instituto Nacional de Neurologia; México.Fil: Abanto-Argomedo, Carlos. Instituto Nacional de Ciencias Neurológicas; Perú.Fil: Amaya, Pablo. Fundación Clínica Valle del Lili; Colombia.Fil: Bayona, Hernán. Hospital Universitario Fundación Santa Fe de Bogotá; Colombia.Fil: Bonardo, Pablo. Hospital Británico de Buenos Aires; Argentina.Fil: Diaz-Escobar, Luis. Hospital de Clínicas; Paraguay.Fil: Gomez Schneider, Maia Macarena. Sanatorio de los Arcos; Argentina.Fil: Góngora-Rivera, Fernando. Hospital Universitario José Eleuterio González; México.Fil: Lavados, Pablo M. Clínica Alemana de Santiago; Chile.Fil: León, Carolina. ISSSTE; México.Fil: Luraschi, Adriana. Hospital Pirovano; Argentina.Fil: Márquez-Romero, Juan Manuel. Instituto Mexicano del Seguro Social; México.Fil: Martins, Sheila C. Hospital de Clínicas de Porto Alegre; Brasil.Fil: Navia, Victor Hugo. Hospital Padre Hurtado; Chile.Fil: Ruiz-Franco, Angelica. Hospital Juárez; México.Fil: Vences, Miguel Angel. Hospital Nacional Edgardo Rebagliati Martins; Perú.Fil: Ameriso, Sebastián Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Vascular; Argentina
Downregulation of E-cadherin in pluripotent stem cells triggers partial EMT
Full text linkEpithelial to mesenchymal transition (EMT) is a critical cellular process that has been well characterized during embryonic development and cancer metastasis and it also is implicated in several physiological and pathological events including embryonic stem cell differentiation. During early stages of differentiation, human embryonic stem cells pass through EMT where deeper morphological, molecular and biochemical changes occur. Though initially considered as a decision between two states, EMT process is now regarded as a fluid transition where cells exist on a spectrum of intermediate states. In this work, using a CRISPR interference system in human embryonic stem cells, we describe a molecular characterization of the effects of downregulation of E-cadherin, one of the main initiation events of EMT, as a unique start signal. Our results suggest that the decrease and delocalization of E-cadherin causes an incomplete EMT where cells retain their undifferentiated state while expressing several characteristics of a mesenchymal-like phenotype. Namely, we found that E-cadherin downregulation induces SNAI1 and SNAI2 upregulation, promotes MALAT1 and LINC-ROR downregulation, modulates the expression of tight junction occludin 1 and gap junction connexin 43, increases human embryonic stem cells migratory capacity and delocalize β-catenin. Altogether, we believe our results provide a useful tool to model the molecular events of an unstable intermediate state and further identify multiple layers of molecular changes that occur during partial EMT.Fil: Aban, Cyntia. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Lombardi, Antonella. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Neiman, Gabriel. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Biani, María Celeste. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: La Greca, Alejandro. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Waisman, Ariel. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Moro, Lucía Natalia. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Sevlever, Gustavo Emilio. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Miriuka, Santiago Gabriel. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Luzzani, Carlos. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina
Consenso sobre la identificación y seguimiento de la esclerosis múltiple secundaria progresiva en Argentina
No full textIntroducción. Existen diferencias significativas en el diagnóstico, la identificación y el seguimiento de pacientes con esclerosis múltiple secundaria progresiva (EMSP) entre los profesionales de la salud a cargo de su tratamiento.
Objetivo. Proveer recomendaciones sobre el tratamiento de los pacientes con EMSP en Argentina con el fin de optimizar
su cuidado.
Desarrollo. Un grupo de neurólogos expertos en esclerosis múltiple de Argentina elaboró un consenso para el tratamiento de pacientes con EMSP en la región mediante metodología de ronda de encuestas a distancia y reuniones presenciales.
Se establecieron 33 recomendaciones basadas en la evidencia publicada y en el criterio de los expertos que participaron.
Las recomendaciones se enfocaron en el diagnóstico y el seguimiento de los pacientes con EMSP.
Conclusión. Las recomendaciones establecidas en el presente consenso permitirían optimizar el cuidado y el seguimiento
de los pacientes con EMSP en Argentina.Fil: Cristiano, Edgardo. Centro de Esclerosis Múltiple de Buenos Aires; Argentina.Fil: Patrucco, Liliana. Hospital Italiano de Buenos Aires; Argentina.Fil: Ysrraelit, María Célica. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.Fil: Alonso, Ricardo. Hospital Ramos Mejía; Argentina. Hospital Universitario Sanatorio Güemes; Argentina.Fil: Balbuena Aguirre, María Eugenia. Hospital de Clínicas José de San Martín; Argentina.Fil: Ballario, Carlos. NeuroRosario; Argentina.Fil: Barboza, Andrés G. Hospital Central de Mendoza; Argentina.Fil: Bestoso, Santiago. Hospital Escuela de Corrientes; Argentina.Fil: Burgos, Marcos. Hospital San Bernardo; Argentina.Fil: Cáceres, Fernando. Instituto de Neurociencias de Buenos Aires; Argentina.Fil: Carrá, Adriana. Hospital Británico; Argentina. Fundación Favaloro; Argentina.Fil: Carnero Contentti, Edgar. Hospital Alemán de Buenos Aires; Argentina.Fil: Deri, Norma. Hospital General de Agudos Juan A. Fernández; Argentina. Centro de Investigaciones Diabaid; Argentina.Fil: Fernández-Liguori, Nora. Hospital Enrique Tornú; Argentina.Fil: Garcea, Orlando. Hospital Ramos Mejía; Argentina.Fil: Hryb, Javier Pablo. Hospital Carlos G. Durand; Argentina.Fil: Jacobo, Miguel. Red Integral Asistencial al Paciente con Esclerosis Múltiple; Argentina.Fil: Kohler, Eduardo. Fundación Sinapsis; Argentina.Fil: Luetic, Geraldine G. Instituto de Neurociencias de Rosario; Argentina.Fil: Mainella, Carolina. Hospital Español de Rosario; Argentina
Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions
No full textAcute and post-acute neurological symptoms, signs and diagnoses have been documented in an increasing number of patients infected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes Coronavirus Disease 2019 (COVID-19). In this review, we aimed to summarize the current literature addressing neurological events following SARS-CoV-2 infection, discuss limitations in the existing literature and suggest future directions that would strengthen our understanding of the neurological sequelae of COVID-19. The presence of neurological manifestations (symptoms, signs or diagnoses) both at the onset or during SARS-CoV-2 infection is associated with a more severe disease, as demonstrated by a longer hospital stay, higher in-hospital death rate or the continued presence of sequelae at discharge. Although biological mechanisms have been postulated for these findings, evidence-based data are still lacking to clearly define the incidence, range of characteristics and outcomes of these manifestations, particularly in non-hospitalized patients. In addition, data from low- and middle-income countries are scarce, leading to uncertainties in the measure of neurological findings of COVID-19, with reference to geography, ethnicity, socio-cultural settings, and health care arrangements. As a consequence, at present a specific phenotype that would specify a post-COVID (or long-COVID) neurological syndrome has not yet been identified.Fil: Beghi, Ettore. Istituto di Ricerche Farmacologiche Mario Negri; Italia.Fil: Giussani, Giorgia. Istituto di Ricerche Farmacologiche Mario Negri; Italia.Fil: Westenberg, Erica. Technical University of Munich; Alemania.Fil: Allegri, Ricardo Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.Fil: Garcia-Azorin, David. Hospital Clínico Universitario Valladolid; España.Fil: Guekht, Alla. Moscow Research and Clinical Center for Neuropsychiatry & Russian National Research Medical University; Rusia.Fil: Frontera, Jennifer. NYU Grossman School of Medicine; Estados Unidos.Fil: Kivipelto, Miia. Karolinska Institutet; Suecia.Fil: Mangialasche, Francesca. Karolinska Institutet; Suecia.Fil: Mukaetova-Ladinska, Elizabeta B. University of Leicester; Reino Unido.Fil: Prasad, Kameshwar. Rajendra Institute of Medical Sciences; India.Fil: Chowdhary, Neerja. World Health Organization; Suiza.Fil: Winkler, Andrea Sylvia. Technical University of Munich; Alemania
Effect of Embryo Aggregation on In Vitro Development of Adipose-Derived Mesenchymal Stem Cell-Derived Bovine Clones
No full textSomatic cell nuclear transfer (SCNT) is a method with unique ability to reprogram the epigenome of a fully differentiated cell. However, its efficiency remains extremely low. In this work, we assessed and combined two simple strategies to improve the SCNT efficiency in the bovine. These are the use of less-differentiated donor cells to facilitate nuclear reprogramming and the embryo aggregation (EA) strategy that is thought to compensate for aberrant epigenome reprogramming. We carefully assessed the optimal time of EA by using in vitro-fertilized (IVF) embryos and evaluated whether the use of adipose-derived mesenchymal stem cells (ASCs) as donor for SCNT together with EA improves the blastocyst rates and quality. Based on our results, we determined that the EA improves the preimplantation embryo development per well of IVF and SCNT embryos. We also demonstrated that day 0 (D0) is the optimal aggregation time that leads to a single blastocyst with uniform distribution of the original blastomeres. This was confirmed in bovine IVF embryos and then, the optimal condition was translated to SCNT embryos. Notably, the relative expression of the trophectoderm (TE) marker KRT18 was significantly different between aggregated and nonaggregated ASC-derived embryos. In the bovine, no effect of the donor cell is observed on the developmental rate, or the embryo quality. Therefore, no synergistic effect of the use of both strategies is observed. Our results suggest that EA at D0 is a simple and accessible strategy that improves the blastocyst rate per well in bovine SCNT and IVF embryos and influence the expression of a TE-related marker. The aggregation of two ASC-derived embryos seems to positively affect the embryo quality, which may improve the postimplantation development.Fil: Savy, Virginia. Universidad de Buenos Aires. Facultad de Agronomía; Argentina.Fil: Alberio, Virgilia. Universidad de Buenos Aires. Facultad de Agronomía; Argentina.Fil: Vans Landschoot, Geraldina. Universidad de Buenos Aires. Facultad de Agronomía; Argentina.Fil: Moro, Lucía Natalia. Fleni. Laboratorio de Investigación Aplicada a las Neurociencias; Argentina.Fil: Olea, Fernanda Daniela. Universidad Favaloro; Argentina.Fil: Rodríguez-Álvarez, Lleretny. Universidad de Concepción; Chile.Fil: Salamone, Daniel Felipe. Universidad de Buenos Aires. Facultad de Agronomía; Argentina
Effects of socioeconomic status in cognition of people with schizophrenia: results from a Latin American collaboration network with 1175 subjects
No full textBackground
Cognition heavily relies on social determinants and genetic background. Latin America comprises approximately 8% of the global population and faces unique challenges, many derived from specific demographic and socioeconomic variables, such as violence and inequality. While such factors have been described to influence mental health outcomes, no large-scale studies with Latin American population have been carried out. Therefore, we aim to describe the cognitive performance of a representative sample of Latin American individuals with schizophrenia and its relationship to clinical factors. Additionally, we aim to investigate how socioeconomic status (SES) relates to cognitive performance in patients and controls.
Methods
We included 1175 participants from five Latin American countries (Argentina, Brazil, Chile, Colombia, and Mexico): 864 individuals with schizophrenia and 311 unaffected subjects. All participants were part of projects that included cognitive evaluation with MATRICS Consensus Cognitive Battery and clinical assessments.
Results
Patients showed worse cognitive performance than controls across all domains. Age and diagnosis were independent predictors, indicating similar trajectories of cognitive aging for both patients and controls. The SES factors of education, parental education, and income were more related to cognition in patients than in controls. Cognition was also influenced by symptomatology.
Conclusions
Patients did not show evidence of accelerated cognitive aging; however, they were most impacted by a lower SES suggestive of deprived environment than controls. These findings highlight the vulnerability of cognitive capacity in individuals with psychosis in face of demographic and socioeconomic factors in low- and middle-income countries.Fil: Sanguinetti Czepielewski, Letícia. Hospital de Clínicas de Porto Alegre; Brasil.Fil: Alliende Serra, Luz Maria. Pontificia Universidad Católica de Chile; Chile.Fil: Castañeda, Carmen Paz. Instituto Psiquiátrico Dr. J. Horwitz Barak; Chile.Fil: Castro, Mariana Nair. Fleni. Grupo de Investigación en Neurociencias
Aplicadas a las Alteraciones de la Conducta; Argentina. Fleni. Servicio de Psiquiatría; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina.Fil: Guinjoan, Salvador. Fleni. Servicio de Psiquiatría; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina.Fil: Massuda, Raffael. Universidade Federal do Paraná; Brasil.Fil: Berberian, Arthur A. Universidade Federal de São Paulo; Brasil.Fil: Fonseca, Ana Olivia. Universidade Federal de São Paulo; Brasil.Fil: Gadelha, Ary. Universidade Federal de São Paulo; Brasil.Fil: Bressan, Rodrigo. Universidade Federal de São Paulo; Brasil.Fil: Crivelaro, Marisa. Instituto de Psiquiatria do HCFMUSP; Brasil.Fil: Louzã, Mario. Instituto de Psiquiatria do HCFMUSP; Brasil.Fil: Undurraga, Juan. Instituto Psiquiátrico Dr J. Horwitz Barak; Chile.Fil: González-Valderrama, Alfonso. Instituto Psiquiátrico Dr J. Horwitz Barak; Chile.Fil: Nachar, Rubén. Instituto Psiquiátrico Dr J. Horwitz Barak; Chile.Fil: Nieto, Rodrigo R. Universidad de Chile; Chile.Fil: Montes, Cristian. Universidad de Chile; Chile.Fil: Silva, Hernan. Universidad de Chile; Chile.Fil: Langer, Álvaro I. Universidad Austral de Chile; Chile.Fil: Schmidt, Carlos. Millennium Institute for Research in Depression and Personality; Chile
Amyloid and anatomical correlates of executive functioning in middle-aged offspring of patients with late-onset Alzheimer's disease
No full textA traditional hallmark of cognitive impairment associated with late-onset Alzheimer´s disease (LOAD) is episodic memory impairment. However, early alterations have been identified in brain regions associated with executive function in asymptomatic, middle-age offspring of patients with LOAD (O-LOAD) compared to those with no family history. We hypothesized that executive function among O-LOAD would correlate with structural and amyloid brain imaging differently from those without a family history of LOAD (control subjects, CS). Executive function, cortical thickness, and in-vivo Aβ deposits were quantified in 30 O-LOAD and 25 CS. Associations were observed among O-LOAD only. Cortical thickness in the left lateral orbitofrontal cortex was positively associated with Design Fluency. The Stroop Color and Word Test, correlated positively with right rostral mid-frontal cortex thickness. Trails Making Test-B was inversely related to left medial orbitofrontal thickness. Tower of London total time was positively associated with β-amyloid deposition in the right precuneus. These results support previous evidence that early executive dysfunction might reflect subtle, early changes in persons at risk of LOAD and suggests that executive function alterations deserve further exploration in the LOAD literature.Fil: Duarte-Abritta, Bárbara. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina.Fil: Sánchez, Stella-Maris. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Física; Argentina.Fil: Abulafia, Carolina. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina. Universidad Católica Argentina; Argentina.Fil: Gustafson, Deborah R. State University of New York; Estados Unidos.Fil: Vázquez, Silvia. Fleni. Departamento de Diagnóstico por Imágenes. Centro de Imágenes Moleculares; Argentina.Fil: Sevlever, Gustavo Emilio. Fleni. Departamento de Neuropatología y Biología Molecular; Argentina.Fil: Castro, Mariana Nair. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Salud Mental,; Argentina. Fleni. Servicio de Psiquiatría; Argentina.Fil: Fiorentini, Leticia. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina. Fleni. Servicio de Psiquiatría; Argentina.Fil: Villarreal, Mirta Fabiana. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Física; Argentina.Fil: Guinjoan, Salvador M. Fleni. Grupo de Investigación en Neurociencias Aplicadas a las Alteraciones de la Conducta; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Salud Mental; Argentina; Universidad de Buenos Aires. Facultad de Psicología. Neurofisiología; Argentina; Laureate Institute for Brain Research; Estados Unidos